Valentia BioPharma

Login

(+34) 963543842

info@valentiabiopharma.com

Innovative drug discovery

against rare diseases
New models of in vivo experimentation

based on Drosophila melanogaster
Firmly committed

to research and biomedical development

Latest News

7TH meeting of rare diseases

24 Feb, 2012 - No Comments
Valentia BioPharma participates in ENSERIOII study

30 Jan, 2012 - No Comments

Our Company

Valentia BioPharma is a biotechnology company born in August 2006 as a University of Valencia spin-off.

After more than 12 years of academic research in the laboratory of Molecular Genetics of Development and Biomedical Models of the University of Valencia, Valentia BioPharma appears as a company devoted to transmit knowledge and scientific research to industry.

Collaborators

Featured Video

Did you know…?
Myotonic Muscular Dystrophy (DMM) or Steinert’s disease is probably the most frequent adult form of congenital myopathy.
Did you know…?
Drosophila melanogaster, commonly known as the fruit fly or the vinegar fly, has already been used for over 100 years as a tool for scientific experimentation.
Did you know…?
The genome sequence of Drosophila melanogaster was completed in the year 2000: more than 50% of the fly protein sequences have their counterpart in mammals.
Did you know…?
Almost 75% of the human genes related to disorders have their counterpart in the fruit fly genome.
Did you know…?
A rare disease affects less than 1 out of 1,500-2,500 people. Nowadays, there are about 7,000 rare diseases, and a few more are found every year, affecting 6-8% of the European Union population.
Did you know…?
The mutation involved in the evolution of Myotonic Dystrophy type 1 is the most frequently diagnosed dystrophy in adults (1 out of 8,000). After 20 years of research, an effective treatment has not been found yet.
Did you know…?
This platform includes the miniaturized growth of flies in 96-well plates and the automated screening of compounds in whole animals that allows us to analyze between 500 and 1,000 compounds per week.
Did you know…?
Valentia BioPharma has developed one of the first automated platforms for drug discovery to fight human disorders using Drosophila Melanogaster.
Did you know…?
75% of the human disease-causing genes are conserved in Drosophila.
Did you know…?
Myotonic dystrophy is the most frequent neuromuscular disorder in adults with a prevalence of 5 cases out of 100,000 people.

Copyright © 2012 Valentia BioPharma. All rights reserved.